Amylin and Lilly Set Date and Time for Conference Call
August 25 2008 - 5:00PM
PR Newswire (US)
Companies Will Discuss Recent FDA Advisory Regarding BYETTA SAN
DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (NASDAQ:AMLN) and Eli Lilly and Company (NYSE:LLY) will Web
cast a conference call on Tuesday, August 26 at 5:00 p.m. ET/2:00
p.m. PT to discuss the recent FDA advisory on BYETTA(R) (exenatide)
injection. Leading the call for Amylin will be Daniel M. Bradbury,
Amylin's President and Chief Executive Officer and Orville G.
Kolterman, M.D., Amylin's Senior Vice President of Research and
Development. Leading the call for Lilly will be Donald Therasse,
M.D., Lilly's Vice President of Global Patient Safety. The call
will be Web cast live through Amylin's corporate Web site and a
recording will be made available following the close of the call.
To access the Web cast, please log on to http://www.amylin.com/
approximately fifteen minutes prior to the call to register,
download and install any necessary audio software. For those
without access to the Internet, the live call may be accessed by
phone by calling (866) 814-1915 (domestic) or (703) 639-1359
(international), passcode 1277182. A replay of the call will also
be available by phone through September 26, 2008 beginning
approximately one hour after the close of the call and can be
accessed at (888) 266-2081 (domestic) or (703) 925-2533
(international), passcode 1277182. About Amylin and Lilly Amylin
Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first-in-class medicines for diabetes,
SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)
injection. Amylin's research and development activities leverage
the company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California with over 2,000 employees nationwide. Further
information on Amylin Pharmaceuticals is available at
http://www.amylin.com/. Through a long-standing commitment to
diabetes care, Lilly provides patients with breakthrough treatments
that enable them to live longer, healthier and fuller lives. Since
1923, Lilly has been the industry leader in pioneering therapies to
help health care professionals improve the lives of people with
diabetes, and research continues on innovative medicines to address
the unmet needs of patients. For more information about Lilly's
current diabetes products visit http://www.lillydiabetes.com/.
Lilly, a leading innovation-driven corporation, is developing a
growing portfolio of first-in-class and best-in-class
pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent
scientific organizations. Headquartered in Indianapolis, Indiana,
Lilly provides answers -- through medicines and information -- for
some of the world's most urgent medical needs. Additional
information about Lilly is available at http://www.lilly.com/.
DATASOURCE: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
CONTACT: Michael York, Senior Director, Investor Relations of
Amylin Pharmaceuticals, Inc., +1-858-552-2200, x8602 Web site:
http://www.amylin.com/ http://www.lilly.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024